thermozymocidin has been researched along with Cardiovascular-Diseases* in 2 studies
2 review(s) available for thermozymocidin and Cardiovascular-Diseases
Article | Year |
---|---|
Targeting ceramide metabolism in obesity.
Obesity is a major health concern that increases the risk for insulin resistance, type 2 diabetes (T2D), and cardiovascular disease. Thus, an enormous research effort has been invested into understanding how obesity-associated dyslipidemia and obesity-induced alterations in lipid metabolism increase the risk for these diseases. Accordingly, it has been proposed that the accumulation of lipid metabolites in organs such as the liver, skeletal muscle, and heart is critical to these obesity-induced pathologies. Ceramide is one such lipid metabolite that accumulates in tissues in response to obesity, and both pharmacological and genetic strategies that reduce tissue ceramide levels yield salutary actions on overall metabolic health. We will review herein why ceramide accumulates in tissues during obesity and how an increase in intracellular ceramide impacts cellular signaling and function as well as potential mechanisms by which reducing intracellular ceramide levels improves insulin resistance, T2D, atherosclerosis, and heart failure. Because a reduction in skeletal muscle ceramide levels is frequently associated with improvements in insulin sensitivity in humans, the beneficial findings reported for reducing ceramides in preclinical studies may have clinical application in humans. Therefore, modulating ceramide metabolism may be a novel, exciting target for preventing and/or treating obesity-related diseases. Topics: Animals; Atherosclerosis; Cardiovascular Diseases; Ceramides; Diabetes Mellitus, Type 2; Dyslipidemias; Fatty Acids, Monounsaturated; Heart Failure; Humans; Insulin Resistance; Lipid Metabolism; Liver; Mitochondria; Molecular Targeted Therapy; Muscle, Skeletal; Myocardium; Obesity | 2016 |
Sphingolipids and cardiovascular diseases: lipoprotein metabolism, atherosclerosis and cardiomyopathy.
Heart disease is widely believed to develop from two pathological processes. Circulating lipoproteins containing the nondegradable lipid, cholesterol, accumulate within the arterial wall and perhaps are oxidized to more toxic lipids. Both lipid accumulation and vascular reaction to the lipids lead to the gradual thickening of the vascular wall. A second major process that in some circumstances is a primary event is the development of a local inflammatory reaction. This might be a reaction to vessel wall injury that accompanies infections, immune disease, and perhaps diabetes and renal failure. In this chapter, we will focus on the relationship between de novo synthesis of sphingolipids and lipid metabolism, atherosclerosis, and cardiomyopathy. Topics: Animals; Apoptosis; Atherosclerosis; Cardiomyopathies; Cardiovascular Diseases; Cholesterol; Coronary Disease; Endothelium, Vascular; Fatty Acids; Fatty Acids, Monounsaturated; Humans; Inflammation; Lipoproteins; MAP Kinase Signaling System; Models, Cardiovascular; Serine C-Palmitoyltransferase; Sphingolipids; Transferases (Other Substituted Phosphate Groups) | 2011 |